Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
about
Tackling ALK in non-small cell lung cancer: the role of novel inhibitorsKRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsConcomitant EML4-ALK rearrangement and EGFR mutation in non small cell lung cancer patients: A literature review of 100 cases.Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review).Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature.Association of epithelial-to-mesenchymal transition circulating tumor cells in non-small cell lung cancer (NSCLC) molecular subgroups.Implications of KRAS mutations in acquired resistance to treatment in NSCLC.KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations.Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment.Q58714451Frequency of actionable alterations in epidermal growth factor receptor wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR)
P2860
Q26740329-C3996939-8E29-4F5A-955B-4BCC3FA5C2A2Q28077570-C675834E-0280-4BBD-B897-B0E218E19455Q30234436-C27A2A03-7D1B-4980-9905-81E6B4331971Q38799845-FE425892-F0BB-4379-BA5B-8CDEC6B8C2A8Q39401616-CE1AFE20-3ED3-420C-8735-6DCB3B4C9895Q41162110-36127DE9-157A-4B62-B278-E732DEA5A1E6Q49218297-F2ED8166-D0DD-4E31-9E7F-DCF94CF98A3EQ49787333-57F4F993-E406-4602-82C4-E3681F2F9922Q49887897-92393725-C72C-49F9-87BB-17AE8EAABE43Q52312436-09D17449-25CA-4BAE-B44F-8E415016B47EQ54109659-4CAFDC52-F408-41C8-A962-21AFB0F35C6CQ54981628-7ED590AD-8231-4CD5-9C25-9C930D6D79F8Q55025386-9AC7E4D0-FD17-43A4-9919-D9957D033E8BQ58714451-0AE00AFD-0436-43FA-B65B-E86425DF4597Q58804420-E4306AC2-88D9-4221-93B8-DAEACA5337BF
P2860
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Nonsquamous, Non-Small-Cell Lu ...... tics, and Response to Therapy.
@en
type
label
Nonsquamous, Non-Small-Cell Lu ...... tics, and Response to Therapy.
@en
prefLabel
Nonsquamous, Non-Small-Cell Lu ...... tics, and Response to Therapy.
@en
P2093
P50
P1433
P1476
Nonsquamous, Non-Small-Cell Lu ...... stics, and Response to Therapy
@en
P2093
Alberto Verlicchi
Alessandra Dubini
Alessandro Gamboni
Claudio Dazzi
Dino Amadori
Gian Michele Turolla
Laura Capelli
Laura Medri
Lucio Crinò
Marita Mariotti
P304
P356
10.1016/J.CLLC.2015.11.004
P407
P577
2015-12-01T00:00:00Z